DE69426527D1 - Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen - Google Patents

Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen

Info

Publication number
DE69426527D1
DE69426527D1 DE69426527T DE69426527T DE69426527D1 DE 69426527 D1 DE69426527 D1 DE 69426527D1 DE 69426527 T DE69426527 T DE 69426527T DE 69426527 T DE69426527 T DE 69426527T DE 69426527 D1 DE69426527 D1 DE 69426527D1
Authority
DE
Germany
Prior art keywords
gene
aspergillus
present
scfv
mould
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426527T
Other languages
English (en)
Other versions
DE69426527T2 (de
Inventor
Leon Gerardus Joseph Frenken
Gorcom Robert F M Van
Johanna G M Hessing
Den Hondel Cornelis Antoni Van
Wouter Musters
Johannes Mariaa Verbakel
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Unilever NV
Original Assignee
Unilever PLC
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO, Unilever NV filed Critical Unilever PLC
Publication of DE69426527D1 publication Critical patent/DE69426527D1/de
Application granted granted Critical
Publication of DE69426527T2 publication Critical patent/DE69426527T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69426527T 1993-06-09 1994-06-09 Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen Expired - Fee Related DE69426527T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP93201660 1993-06-09
EP93201661 1993-06-09
EP93201706 1993-06-14
PCT/EP1994/001906 WO1994029457A2 (en) 1993-06-09 1994-06-09 Process for producing fusion proteins comprising scfv fragments by a transformed mould

Publications (2)

Publication Number Publication Date
DE69426527D1 true DE69426527D1 (de) 2001-02-08
DE69426527T2 DE69426527T2 (de) 2001-08-30

Family

ID=27235312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426527T Expired - Fee Related DE69426527T2 (de) 1993-06-09 1994-06-09 Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen

Country Status (10)

Country Link
EP (1) EP0702721B1 (de)
JP (1) JPH08511160A (de)
AT (1) ATE198490T1 (de)
AU (1) AU7123494A (de)
CA (1) CA2162878A1 (de)
DE (1) DE69426527T2 (de)
DK (1) DK0702721T3 (de)
ES (1) ES2155854T3 (de)
FI (1) FI114870B (de)
WO (1) WO1994029457A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
DK0826054T3 (da) * 1995-05-18 2004-04-19 Genencor Int Ekspression af glycosyltransferase i Aspergillus
AU8437398A (en) 1997-06-13 1998-12-30 Unilever Plc Bleaching enzymes
EP0954978B1 (de) 1998-03-12 2011-11-30 VHsquared Limited Produkten die inaktivierte Hefen oder Schimmel enthalten, die auf ihrer Aussenoberfläche aktive Antikörper haben
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
AU6153100A (en) 1999-07-27 2001-02-13 Davis, Paul James Bleaching detergent compositions
EP1368380B1 (de) 2000-12-19 2009-09-02 Unilever N.V. Stabilisierung von schwerkettigen Kamelantikörpern durch Kaliumsalze
BR0307216A (pt) * 2002-01-28 2005-12-20 Medarex Inc Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
EP2557090A3 (de) 2006-12-19 2013-05-29 Ablynx N.V. Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2008081031A2 (en) * 2007-01-05 2008-07-10 Novozymes A/S Methods of increasing the production yield of a secreted antibody in a filamentous fungus by overexpression of the chaperone bip
EP2260058A2 (de) 2008-04-07 2010-12-15 Ablynx N.V. Variable einzeldomänen gegen notch-signalwege
CN102388069B (zh) 2009-04-10 2016-01-20 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
US9403898B2 (en) 2009-05-07 2016-08-02 Novozymes Biopharma Dk A/S Method for purifying albumin
RU2016103067A (ru) 2009-06-05 2018-11-20 Аблинкс Нв Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
EP2621953B1 (de) 2010-09-30 2017-04-05 Ablynx N.V. Biologische stoffe im zusammenhang mit c-met
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104271598A (zh) 2011-06-23 2015-01-07 埃博灵克斯股份有限公司 针对IgE的免疫球蛋白单可变结构域
CA2850261C (en) 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
DK3071598T3 (da) 2013-05-29 2021-09-13 Vybion Inc Enkeltkædede intrabodies, der ændrer nedbrydning af huntingtin-mutant
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2016097313A1 (en) 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
CN114920848A (zh) 2015-05-13 2022-08-19 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
HUE045437T2 (hu) 2015-05-13 2019-12-30 Ablynx Nv TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
EP3526253A1 (de) 2016-10-14 2019-08-21 Institut Curie Neuer anti-lsp1-antikörper
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
EP3624854A1 (de) 2017-05-16 2020-03-25 Université de Strasbourg Proteinwirkstoffkonjugate und deren verwendung in der behandlung von krebs
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
KR20200013247A (ko) 2017-06-02 2020-02-06 아블린쓰 엔.브이. 아그레칸 결합 면역글로불린
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
EP3630847A1 (de) 2017-06-02 2020-04-08 Merck Patent GmbH Adamts-bindende immunoglobuline
EP3658915A1 (de) 2017-07-28 2020-06-03 Institut Curie Neue subpopulationen von tumorassoziierten fibroblasten als marker zur prognose von immuntherapiebehandlungen
AR114269A1 (es) 2018-02-26 2020-08-12 Ablynx Nv Secuencias nucleotídicas mejoradas que codifican para péptidos de unión
KR101875564B1 (ko) * 2018-05-24 2018-07-09 국민대학교산학협력단 포도당 및 글리세롤을 이용한 유가식 배양을 통한 리시놀레산으로 오메가-하이드록시운덱-9-에논산의 생물전환공정
EP3636657A1 (de) 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4263610A1 (de) 2020-12-18 2023-10-25 Ablynx N.V. T-zell-rekrutierende polypeptide auf basis von tcr-alpha/beta-reaktivität
EP4337691A1 (de) 2021-05-12 2024-03-20 Université de Strasbourg Für phosphoryliertes h2ax spezifischer einzeldomänenantikörper und dessen verwendungen
WO2023151894A1 (en) 2022-02-11 2023-08-17 Henkel Ag & Co. Kgaa Process for the synthesis of alpha-methylene-gamma-butyrolactone
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539395A1 (de) * 1990-07-16 1993-05-05 Alko Group Ltd. Immunglobulinherstellung durch trichoderma
WO1993008300A1 (en) * 1991-10-18 1993-04-29 The University Of Calgary Expression-secretion vectors for the production of biologically active fv fragments
IT1270866B (it) * 1993-03-10 1997-05-13 Eniricerche Spa Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis

Also Published As

Publication number Publication date
AU7123494A (en) 1995-01-03
WO1994029457A2 (en) 1994-12-22
EP0702721A1 (de) 1996-03-27
DE69426527T2 (de) 2001-08-30
FI114870B (fi) 2005-01-14
JPH08511160A (ja) 1996-11-26
DK0702721T3 (da) 2001-05-21
ES2155854T3 (es) 2001-06-01
CA2162878A1 (en) 1994-12-22
FI955446A0 (fi) 1995-11-13
FI955446A (fi) 1995-12-11
EP0702721B1 (de) 2001-01-03
ATE198490T1 (de) 2001-01-15
WO1994029457A3 (en) 1995-03-09

Similar Documents

Publication Publication Date Title
DE69426527D1 (de) Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
EP0042246B1 (de) Plasmid
ATE97957T1 (de) Verfahren zur herstellung des rekombinanten menschlichen faktors viii:c.
FI973468A (fi) Hampaiden valkaisemiseen tai ihon ja limakalvojen sairauksien hoitoon käytettävien valmisteiden valmistusmenetelmä
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
HUT46356A (en) Process for producing the preprotein of apc polypeptide and the dna encoding it, as well as for the diagnostic utilization of the dna and the protein
GB9220667D0 (en) Improvements in or relating to dioic acids
DE3471092D1 (en) Composition essentially consisting of trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, utilization of same and process for its preparation; cycloaliphatic ketone and alcohol intermediates
FI942691A0 (fi) Menetelmä tuottaa/erittää proteiinia transformoidun homeen avulla käyttämällä Aspergilluksen endoksylanaasi II-geenistä saatuja ekspressioita/erittämistä sääteleviä alueita
ATE233314T1 (de) Eine sekretionssequenz für die herstellung von heterologen proteinen in hefe
PL321039A1 (en) Production of human insulin
CA2286366A1 (en) Transgenic expression in genital tract and sexual accessory glands
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
Slavkin et al. Molecular aspects of tooth morphogenesis and differentiation
BR9609041A (pt) "terapia de substituição para cáries dentais".
DE3175357D1 (en) Dna sequences encoding various allelic forms of mature thaumatin, recombinant plasmids comprising said dna's and a process for their preparation, bacterial cultures comprising said recombinant plasmids, and method for producing mature thaumatin
HU9401604D0 (en) Production of proteins using fb2 protein
HUP9904219A2 (hu) Eljárás és készítmények interferon-alfa-nukleinsavak bevitelére és expressziójára
PT93614A (pt) Estirpe de levedura melhorada para a producao de proteinas heterologas maduras,em particular hirudina, e processo para a preparacao da hirudina correspondente
DE69530647D1 (de) Für biosynthetische Insulinvorstufen kodierende DNA-Sequenzen und Verfahren zur Herstellung von Insulin
WO1991005045A1 (en) PORCINE LACTOFERRIN AMINO ACID AND cDNA SEQUENCE
DE3767629D1 (de) Menschlicher b-zellen-differenzierungsfaktor und verfahren zu dessen herstellung.
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
GR3034006T3 (en) Method for obtaining an increased production of a producing celline by using a fusion protocol.
IE883018L (en) Expression of transforming growth factor b2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee